pindolol has been researched along with fluoxetine in 54 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 27 (50.00) | 18.2507 |
2000's | 19 (35.19) | 29.6817 |
2010's | 8 (14.81) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Caron, G; Ermondi, G | 1 |
Morphy, R; Rankovic, Z | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Abraham, MH; Acree, WE; Ibrahim, A | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Janowsky, DS; Overstreet, DH; Rezvani, AH | 1 |
Bourson, A; Carolo, C; Petit, N; Sleight, AJ; Zwingelstein, C | 1 |
Hietala, J; Kuoppamäki, M; Laakso, A; Pälvimäki, EP; Syvälahti, E | 1 |
Paré, WP; Tejani-Butt, SM; Yang, J | 1 |
Tejani-Butt, SM; Yang, J | 1 |
Dreshfield, LJ; Engleman, EA; Perry, KW; Wong, DT | 1 |
Koran, LM; Maloney, A; Mueller, K | 1 |
Bril, T; Demedts, P; Maes, M; Neels, H; Van de Vyvere, J; Vandoolaeghe, E; Wauters, A | 1 |
Desnyder, R; Maes, M; Vandoolaeghe, E | 1 |
Anand, A; Berman, RM; Charney, DS; Darnell, AM; Miller, HL | 1 |
Demedts, P; Maes, M; Neels, H; Van Hunsel, F; Vandoolaeghe, E; Wauters, A | 1 |
Alvarez, E; Artigas, F; Faries, D; Gilaberte, I; Pérez, V | 1 |
Bordet, R; Dupuis, B; Thomas, P | 1 |
Terao, T | 1 |
Dreshfield, LJ; Rocco, VP; Wong, DT | 1 |
Demedts, P; Maes, M; Meltzer, HY; Neels, H; Vandoolaeghe, E; Wauters, A; Westenberg, H | 1 |
Paré, WP; Tejani-Butt, SM; Zafar, HM | 1 |
Browning, RA; Dailey, JW; Jobe, PC; Merrill, MA; Wood, AV | 1 |
Iyengar, S; Li, DL; Simmons, RM | 1 |
Lin, A; Maes, M; Scharpé, S; Vandoolaeghe, E; Verkerk, R | 1 |
Alvarez, E; Artigas, F; Pérez, V; Puigdemont, D; Soler, J | 1 |
Campens, D; Libbrecht, I; Maes, M; Meltzer, HY; van Hunsel, F | 1 |
Anand, A; Berman, RM; Cappiello, A; Charney, DS; Hu, XS; Miller, HL; Oren, DA | 1 |
Moser, PC; Sanger, DJ | 1 |
Hirao, N; Koshino, Y; Nakamura, M; Shiraishi, J; Wada, Y | 1 |
Gobert, A; Millan, MJ | 1 |
Fornal, CA; Jacobs, BL; Martin, FJ; Metzler, CW | 1 |
Dawson, LA; Nguyen, HQ | 1 |
Alvarez, E; Artigas, F; Boto, B; Buesching, DP; Demitrack, M; Gilaberte, I; Obenchain, RL; Pérez Sola, V; Sacristán, JA | 1 |
Dawson, LA; Nguyen, HQ; Schechter, LE; Smith, DI | 1 |
Faries, DE; Feng, J; Tamura, RN | 1 |
Broft, A; Laruelle, M; Martinez, D | 1 |
Alvarez, E; Artigas, F; Gilaberte, I; Pérez, V; Puiigdemont, D | 1 |
Cremaschi, GA; Edgar, VA; Genaro, AM; Sterin-Borda, L | 1 |
McCreary, AC; Rasmussen, K; Shanks, EA | 1 |
Anand, A; Berman, RM; Charney, DS; Lynch-Colonese, K; Perry, EB; Sanacora, G | 1 |
Anjaneyulu, M; Chopra, K | 1 |
Albert, PR; Bakish, D; Du, L; Hrdina, P; Lemonde, S | 1 |
Alvarez, E; de Diego-Adeliño, J; Pérez, V; Pérez-Egea, R; Portella, MJ; Puigdemont, D | 1 |
Alvarez, E; Artigas, F; de Diego-Adeliño, J; Pérez, V; Pérez-Egea, R; Portella, MJ; Puigdemont, D | 1 |
Bregman, T; Diwan, M; Fletcher, PJ; Hamani, C; Nobrega, JN; Raymond, R; Scott, B; Volle, J | 1 |
3 review(s) available for pindolol and fluoxetine
Article | Year |
---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies.
Topics: Animals; Brain; Cerebrovascular Circulation; Clinical Trials as Topic; Depressive Disorder, Major; Drug Synergism; Fluoxetine; Humans; Paroxetine; Pindolol; Rats; Selective Serotonin Reuptake Inhibitors; Tomography, Emission-Computed | 2000 |
15 trial(s) available for pindolol and fluoxetine
Article | Year |
---|---|
Alterations in iron metabolism and the erythron in major depression: further evidence for a chronic inflammatory process.
Topics: Acute-Phase Reaction; Adrenergic beta-Antagonists; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Count; Erythrocyte Indices; Female; Ferritins; Fluoxetine; Hematocrit; Hemoglobinometry; Humans; Iron; Male; Middle Aged; Pindolol; Transferrin; Trazodone | 1996 |
Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Personality Inventory; Pindolol; Serotonin Antagonists; Trazodone | 1996 |
Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Pindolol; Placebos; Treatment Outcome | 1997 |
Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments.
Topics: Acute-Phase Proteins; Adrenergic beta-Antagonists; Adult; Aged; Alpha-Globulins; Antidepressive Agents, Second-Generation; Beta-Globulins; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; gamma-Globulins; Humans; Male; Middle Aged; Pindolol; Serum Albumin; Trazodone; Treatment Failure | 1996 |
Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Pindolol; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 1997 |
Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Personality Inventory; Pindolol; Piperazines; Trazodone; Treatment Outcome | 1997 |
Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.
Topics: Adult; Aged; Alanine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine; Asparagine; Aspartic Acid; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Excitatory Amino Acids; Female; Fluoxetine; Glycine; Histidine; Humans; Male; Middle Aged; Personality Inventory; Pindolol; Prognosis; Selective Serotonin Reuptake Inhibitors; Serine; Taurine; Threonine; Trazodone; Treatment Outcome | 1998 |
A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Topics: Adult; Ambulatory Care; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Pindolol; Placebos; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 1999 |
Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.
Topics: Adult; Aged; Analysis of Variance; Depressive Disorder; Fluoxetine; Humans; Mianserin; Middle Aged; Pindolol; Psychiatric Status Rating Scales | 1999 |
The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial.
Topics: Adult; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pindolol | 1999 |
Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Cost-Benefit Analysis; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Health Care Costs; Humans; Male; Middle Aged; Pindolol; Serotonin Antagonists | 2000 |
Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors.
Topics: Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Methods; Pindolol; Survival Analysis; Treatment Outcome | 2001 |
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Connecticut; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Hospitals, Veterans; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Pindolol; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Veterans | 2004 |
A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes.
Topics: Adult; Citalopram; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Humans; Male; Pindolol; Recurrence; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2010 |
Pindolol augmentation enhances response outcomes in first depressive episodes.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Kaplan-Meier Estimate; Male; Pindolol; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Treatment Outcome; Young Adult | 2009 |
36 other study(ies) available for pindolol and fluoxetine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Drug-induced reductions in ethanol intake in alcohol preferring and Fawn-Hooded rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Drinking Behavior; Ethanol; Feeding Behavior; Fluoxetine; Male; Pindolol; Piperazines; Rats; Rats, Inbred Strains; Rats, Wistar; Scopolamine; Self Administration; Serotonin Receptor Agonists; Species Specificity; Verapamil | 1991 |
Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment.
Topics: Animals; Binding Sites; Down-Regulation; Fluoxetine; Hypothalamus; Kinetics; Male; Membranes; Pindolol; Rats; Receptors, Serotonin; Sensitivity and Specificity; Serotonin; Tritium | 1995 |
Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments.
Topics: Adrenergic beta-1 Receptor Agonists; Animals; Autoradiography; Brain Chemistry; Citalopram; Fluoxetine; Image Processing, Computer-Assisted; Imipramine; Iodocyanopindolol; Male; Pindolol; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Up-Regulation | 1994 |
Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Body Weight; Brain; Carrier Proteins; Depression; Dioxanes; Fluoxetine; Idazoxan; Male; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Pindolol; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Adrenergic; Species Specificity; Stress, Psychological; Swimming; Symporters | 1994 |
A time course of altered thyroid states on the noradrenergic system in rat brain by quantitative autoradiography.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Animals; Autoradiography; Body Weight; Brain Chemistry; Dioxanes; Fluoxetine; Idazoxan; Male; Norepinephrine; Pindolol; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Presynaptic; Thyroid Gland; Thyroidectomy; Time Factors | 1994 |
Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors.
Topics: Analysis of Variance; Animals; Dose-Response Relationship, Drug; Fluoxetine; Hypothalamus; Infusions, Parenteral; Kinetics; Male; Microdialysis; Pindolol; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Antagonists | 1996 |
Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?
Topics: 1-Naphthylamine; Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Clomipramine; Drug Synergism; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Pindolol; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Selective serotonin reuptake inhibitors plus pindolol. The REEP.
Topics: Depressive Disorder; Fluoxetine; Humans; Paroxetine; Pindolol; Selective Serotonin Reuptake Inhibitors; Sympatholytics | 1997 |
Selective serotonin reuptake inhibitors plus pindolol.
Topics: Depressive Disorder; Drug Interactions; Fluoxetine; Humans; Pindolol; Selective Serotonin Reuptake Inhibitors; Sympatholytics | 1997 |
Greater effects of fluoxetine and its combination with (-)-pindolol in elevating hypothalamic serotonin in rats during dark hours.
Topics: Adrenergic beta-Antagonists; Animals; Circadian Rhythm; Darkness; Drug Synergism; Fluoxetine; Hypothalamus; Male; Microdialysis; Pindolol; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin | 1997 |
Effect of acute or repeated stress on behavior and brain norepinephrine system in Wistar-Kyoto (WKY) rats.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Autoradiography; Behavior, Animal; Chronic Disease; Fluoxetine; Iodine Radioisotopes; Limbic System; Male; Norepinephrine; Pindolol; Rats; Rats, Inbred WKY; Restraint, Physical; Stress, Physiological; Tritium | 1997 |
Enhancement of the anticonvulsant effect of fluoxetine following blockade of 5-HT1A receptors.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Brain; Cyclohexylamines; Drug Interactions; Female; Fenclonine; Fluoxetine; Norepinephrine; Pindolol; Rats; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Seizures; Serotonin; Serotonin Antagonists | 1997 |
5HT1A receptor antagonists enhance the functional activity of fluoxetine in a mouse model of feeding.
Topics: Animals; Cyclohexylamines; Drinking Behavior; Drug Synergism; Feeding Behavior; Fluoxetine; Male; Mice; Mice, Inbred Strains; Pindolol; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists | 1998 |
5-HT1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Drug Interactions; Fluoxetine; Male; Monoamine Oxidase Inhibitors; Oxazoles; Pindolol; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Swimming | 1999 |
Pindolol potentiates the effect of fluoxetine on hippocampal seizures in rats.
Topics: Animals; Drug Synergism; Fluoxetine; Hippocampus; Male; Pindolol; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Seizures; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists | 1999 |
Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B re
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Betaxolol; Dopamine; Fluoxetine; Frontal Lobe; Guinea Pigs; Humans; Male; Microdialysis; Norepinephrine; Pindolol; Piperazines; Propanolamines; Pyridines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1B; Receptors, Adrenergic, beta; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists | 1999 |
Pindolol, a putative 5-hydroxytryptamine(1A) antagonist, does not reverse the inhibition of serotonergic neuronal activity induced by fluoxetine in awake cats: comparison to WAY-100635.
Topics: Animals; Cats; Drug Interactions; Fluoxetine; Male; Neurons; Pindolol; Piperazines; Pyridines; Raphe Nuclei; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists | 1999 |
The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol.
Topics: Animals; Autoreceptors; Drug Synergism; Extracellular Space; Fluoxetine; Male; Microdialysis; Oxadiazoles; Pindolol; Piperazines; Propanolamines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists | 2000 |
Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: a microdialysis study.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dose-Response Relationship, Drug; Fluoxetine; Frontal Lobe; Male; Microdialysis; Pindolol; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Time Factors | 2000 |
Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von Mises test.
Topics: Adrenergic beta-Antagonists; Algorithms; Antidepressive Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Models, Statistical; Pindolol; Sample Size; Statistical Distributions; Survival Analysis; Time Factors; Treatment Outcome | 2000 |
Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine.
Topics: Adrenergic beta-Antagonists; Animals; Antidepressive Agents, Second-Generation; Autonomic Nervous System; B-Lymphocytes; CD4-CD8 Ratio; Cell Division; Chronic Disease; Cyclic AMP; Cyclic GMP; Disease Models, Animal; Female; Fluoxetine; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Mitogens; Muscarinic Antagonists; Pindolol; Quinuclidinyl Benzilate; Radioligand Assay; Receptors, Adrenergic, beta; Receptors, Muscarinic; Stress, Psychological; T-Lymphocytes; Tritium | 2002 |
Attenuation of the effects of fluoxetine on serotonergic neuronal activity by pindolol in rats.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Neurons; Pindolol; Pons; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Treatment Outcome | 2004 |
Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice.
Topics: Analgesics; Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fluoxetine; Hot Temperature; Hyperalgesia; Male; Mice; Ondansetron; Pindolol; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT2; Ritanserin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Streptozocin; Time Factors; Touch | 2004 |
Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response.
Topics: Adrenergic beta-Antagonists; Adult; Alleles; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzimidazoles; Cohort Studies; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Pindolol; Piperazines; Polymorphism, Genetic; Promoter Regions, Genetic; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Triazoles | 2004 |
Deep brain stimulation and fluoxetine exert different long-term changes in the serotonergic system.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Brain; Deep Brain Stimulation; Fluoxetine; Hippocampus; Iodine Radioisotopes; Pindolol; Prefrontal Cortex; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tritium | 2018 |